Phoska Biopharma Overview
- Year Founded
-
2019
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Investors
-
3
Phoska Biopharma General Information
Description
Operator of an artificial intelligence-based platform company based in Singapore. The company's biotech platform is used for multiple orphan diseases as well as in large neurodegenerative conditions, enabling healthcare companies to develop novel treatments for neurological diseases.
Contact Information
Corporate Office
- 79 Science Park Drive
- Number 06-01 Cintech IV
- Singapore, 118264
- Singapore
Corporate Office
- 79 Science Park Drive
- Number 06-01 Cintech IV
- Singapore, 118264
- Singapore
Phoska Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Secondary Transaction - Private | Completed | Startup | ||||
| 2. Seed Round | 31-Mar-2023 | Completed | Startup | |||
| 1. Seed Round | 18-Jul-2020 | $1.35M | $1.35M | Completed | Startup |
Phoska Biopharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Phoska Biopharma Patents
Phoska Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022263927-A2 | Plasmalogen derivatives and uses thereof | Inactive | 17-Jun-2021 | ||
| WO-2022263927-A3 | Plasmalogen derivatives and uses thereof | Inactive | 17-Jun-2021 |
Phoska Biopharma Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Albrekca | Corporation | Minority | ||
| Angel (individual) | Minority | |||
| SPRIM Global Investments | Holding Company | Minority |
Phoska Biopharma Investments (1)
Phoska Biopharma’s most recent deal was a Corporate Asset Purchase with Op2Lysis (Certain Assets). The deal was made on 10-Apr-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Op2Lysis (Certain Assets) | 10-Apr-2026 | Corporate Asset Purchase | Buildings and Property |
Phoska Biopharma FAQs
-
When was Phoska Biopharma founded?
Phoska Biopharma was founded in 2019.
-
Where is Phoska Biopharma headquartered?
Phoska Biopharma is headquartered in Singapore, Singapore.
-
What industry is Phoska Biopharma in?
Phoska Biopharma’s primary industry is Biotechnology.
-
Is Phoska Biopharma a private or public company?
Phoska Biopharma is a Private company.
-
What is Phoska Biopharma’s current revenue?
The current revenue for Phoska Biopharma is .
-
How much funding has Phoska Biopharma raised over time?
Phoska Biopharma has raised $3.55M.
-
Who are Phoska Biopharma’s investors?
Albrekca, , and SPRIM Global Investments have invested in Phoska Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process